Comparative Pharmacology
Head-to-head clinical analysis: BLOCADREN versus TIMOPTIC IN OCUDOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLOCADREN versus TIMOPTIC IN OCUDOSE.
BLOCADREN vs TIMOPTIC IN OCUDOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective beta-adrenergic receptor antagonist; blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure.
Timolol is a non-selective beta-adrenergic receptor antagonist (beta-1 and beta-2) that reduces intraocular pressure by decreasing aqueous humor production, likely by blocking beta-adrenergic receptors in the ciliary epithelium.
Hypertension: initial 10 mg PO twice daily, increase gradually to 20-40 mg/day; maximum 60 mg/day. Post-MI: 10 mg PO twice daily starting 1-4 weeks post-infarction.
Instill 1 drop of 0.25% or 0.5% solution in the affected eye(s) twice daily.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; prolonged in renal impairment (up to 24 hours) and elderly; dose adjustment required in CrCl <35 mL/min
Terminal elimination half-life is 4-6 hours in adults; prolonged to 8-12 hours in renal impairment.
Primarily renal (80-95% unchanged), minor hepatic metabolism to inactive metabolites, minimal fecal excretion (<5%)
Renal: approximately 80% as unchanged drug and metabolites; biliary/fecal: minor (less than 10%).
Category C
Category C
Ophthalmic Beta Blocker
Ophthalmic Beta Blocker